ArticleAnnals of translational medicine2015
Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014.
Article in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a blood borne pathogen that causes chronic liver disease and afflicts 170 million people world-wide. While direct acting antivirals now provide a highly effective means to cure those infected with HCV, there is no vaccine to prevent infection. Published in Science Translational Medicine, de Jong et al. [2014] show that highly potent neutralizing antibodies (NAbs) directed to one of the surface glycoproteins of HCV, E2, can not only prevent infection but can also eliminate established infection in experimental animal models of HCV. They provide compelling evidence that for HCV to maintain a chronic infection, it must infect new hepatocytes; infection cannot be sustained in reservoirs of infected cells alone and that E2-specific NAbs are sufficient to cure an infection. In addition, the manuscript further supports the importance of NAbs in preventing, controlling and possibly curing HCV. Thus NAbs are not only essential to the development of prophylactic vaccines but may yet have a role in therapeutic approaches to HCV treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.